2011, Number 1
PDF size: 970.70 Kb.
ABSTRACTGout, is one of the most antique and complex diseases known and it has doubled its prevalence in recent years, specially in the United States and other developed countries, due to the increased number of multiple comorbidities, advanced age, hyperuricemia, diet and life style factors. Indeed, the more we know about this disease, the more complex it becomes. This Review has different objectives; to understand the importance of risk factors for developing gout and to review the last decade advances in treatment. Making emphasis in the employment of dietry measures and pharmacologic treatments for active gouty arthritis. Not only focused in the disease treatment but also, and most importantly, in the prevention of gout flares and the importance of lowering hyperuricemia levels. In addition, new techniches for the developing of tophus in order to analyze how this can make a difference in the treatment and the patient's follow up. A revision among the newest therapies for the managment of acute flares, such as febuxostat and pegylated uricase urate-lowering theraphy, just recently approved on September 2010 by the FDA for gout treatment. Hoping that this review helps their readers comprehend the complexity of this disease, and helping lead the managment of hyperuricemia and gout, reducing risk and having improvements in patient-centered outcomes.
16.Ortiz-Bravo E; Sieck MS; Schumacher HR Jr Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. Arthritis Rheum 1993 Sep;36(9):1274-85.